BioSpace News Archive

Pall Corporation, a global leader in filtration, separation and purification, today announced a newly formed 2020 strategic partnership between its Medical division and the Association for Professionals in Infection Control and Epidemiology (APIC).

Aro Biotherapeutics announced the appointments of Martin McMahon, PhD, and Ronald V. Swanson, PhD, to its Scientific Advisory Board (SAB).

Stilla Technologies, a leading provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, has just raised €20 million ($22 million) in a Series B funding round that brought in a new investor, the Chinese group TUS-Holdings, alongside the participation of existing investors Illumina Ventures, Kurma Partners, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement and Idinvest Partners.

SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cell therapy, today announced preliminary financial results for 2019. SIRION’s annual service and licensing revenues in 2019 exceeded €10M (US$11.2M).

Feb. 11, 2020 13:00 UTC Live Webcast Scheduled to Begin at Noon ET Monday, February 24, 2020 LEXINGTON, Mass.--( BUSINESS WIRE )-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research & Development Day on Monday, February 24, 2020, to provide an update on current late-sta

Co-Diagnostics, Inc. (Nasdaq: CODX), today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,324,676 shares of its common stock, at a purchase price per share of $3.08, in a registered direct offering priced at-the-marked under the Nasdaq rules.

yclo Therapeutics, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the last patient has undergone the final assessment in its Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to NPC patients.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval application to the U.S. Food and Drug Administration for its myChoice® CDx test to help identify women with advanced ovarian cancer who are potential candidates for maintenance therapy with Lynparza® in combination with bevacizumab.

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full-year 2019 and its 2020 outlook on Tuesday, Feb. 25 at 9 a.m. ET.

Marker Therapeutics, Inc. (NASDAQ: MRKR), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Marker’s planned trial investigating safety and efficacy of its novel MultiTAA T cell therapy in patients with post-transplant acute myeloid leukemia (AML).